Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 1 of the 27 sources its claims cite were checked for support.

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

Open access
Wigal, Timothy, Brams, Matthew, Gasior, Maria, Gao, Joseph, Squires, Liza, Giblin, John, 316 Study Group · 2010 · Behavioral and Brain Functions

Abstract

BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment. METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, double-blind, placebo-controlled crossover phase. Efficacy assessments included the Permanent Product Measure of Performance (PERMP) total score (attempted+correct) measured predose and from 2 to 14 hours postdose, averaged across postdose sessions (primary) and at each time point vs placebo (secondary), and ADHD Rating Scale IV (ADHD-RS-IV) with adult prompts at baseline and crossover visits. Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms. RESULTS: Of 127 randomized subjects, 105 were in the intention-to-treat population and 103 completed the study. While receiving LDX vs placebo, adults had greater improvement (P < .0001) in average PERMP total scores as measured by difference in least squares (LS) mean (95% CI): 23.4 (15.6, 31.2). Absolute (P or=10%) during dose optimization were decreased appetite, dry mouth, headache, and insomnia; no TEAEs >or=5% were reported during crossover phase for adults receiving LDX. CONCLUSIONS: LDX significantly improved PERMP scores vs placebo and maintained improvement throughout the day from the first (2 hours) to last (14 hours) postdose time point vs placebo in adults with ADHD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00697515. Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) http://www.clinicaltrials.gov/ct2/show/NCT00697515?term=NCT00697515&rank=1.

Overview

CoChat Summary

TL;DR

In adults with ADHD, lisdexamfetamine dimesylate (LDX) significantly improved simulated workplace performance and ADHD symptoms versus placebo across the day. Efficacy was demonstrated from 2 to 14 hours postdose, with a safety profile consistent with long-acting stimulants.

Key findings

  • On the primary endpoint, average postdose PERMP total score was significantly greater with LDX vs placebo: difference in LS mean (95% CI) 23.4 (15.6, 31.2), P < .0001.
  • LDX improved PERMP total scores at every postdose time point from 2 to 14 hours versus placebo (absolute values P ≤ .0017; change from predose P < .001 for each time point).
  • ADHD-RS-IV total scores improved significantly with LDX vs placebo: difference in LS mean (95% CI) −11.5 (−14.2, −8.9), P < .0001; CGI-I also favored LDX (P < .0001 by Prescott’s test).
  • During dose optimization, common TEAEs (≥10%) were decreased appetite (36.6%), dry mouth (30.3%), headache (19.7%), and insomnia (18.3%); during crossover, no TEAEs were reported by ≥5% of subjects receiving LDX.

Methods

  • Randomized, double-blind, placebo-controlled, 2-way crossover study with an open-label dose-optimization phase, conducted at 5 US centers in adults aged 18–55 years with ADHD.
  • After 4-week open-label LDX dose optimization (30–70 mg/d), 127 subjects were randomized; 105 were in the intention-to-treat population and 103 completed the study.
  • Efficacy was assessed in a simulated adult workplace environment using PERMP at predose and 2, 4, 8, 10, 12, and 14 hours postdose, plus ADHD-RS-IV with adult prompts and CGI; primary analysis used a linear mixed-effects ANOVA with treatment, period, and sequence as fixed effects and subject as random effect.

Limitations

  • The paper states the study duration was relatively short; the PERMP setting may increase testing-related arousal, though the simulated AWE includes practice and repeated testing to dampen this; the AWE is only analogous to real-world employment in requiring attention, mental effort, and quantifiable written work.
  • The paper states exclusions of subjects with active cardiovascular conditions, other unstable medical conditions, or comorbid psychiatric disorders may limit applicability to clinically encountered populations; the expected 15% dropout rate was exceeded because a hurricane closed one study site.
  • Evident from the text: all randomized subjects first underwent open-label dose optimization, so the double-blind comparison was conducted in subjects who tolerated and responded adequately to LDX, which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1744-9081-6-34

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study design. (AWE = adult workplace environment; LDX = lisdexamfetamine dimesylate).
Figure 1 Study design. (AWE = adult workplace environment; LDX = lisdexamfetamine dimesylate).CC BY · PubMed Central
Figure 2 LS Mean (SE) change from predose in PERMP total score from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP = Permanent Product Measure of Performance). LDX-purple diamonds; Placebo-green circles. * P < .001 LDX vs placebo.
Figure 2 LS Mean (SE) change from predose in PERMP total score from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP = Permanent Product Measure of Performance). LDX-purple diamonds; Placebo-green circles. * P < .001 LDX vs placebo.CC BY · PubMed Central
Figure 3 LS mean (SE) change from predose in PERMP-A and PERMP-C scores from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP-A/-C = Permanent Product Measure of Performance-Attempted/-Correct). PERMP-A: LDX-purple diamonds; Placebo-green diamonds; PERMP-C: LDX-blue circles; Placebo-orange circles.* P < .001 LDX vs placebo.
Figure 3 LS mean (SE) change from predose in PERMP-A and PERMP-C scores from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP-A/-C = Permanent Product Measure of Performance-Attempted/-Correct). PERMP-A: LDX-purple diamonds; Placebo-green diamonds; PERMP-C: LDX-blue circles; Placebo-orange circles.* P < .001 LDX vs placebo.CC BY · PubMed Central
Figure 4 ADHD-RS-IV total scores at baseline and visit 5/6 and difference in LS mean (95% CI) between LDX and placebo during the double-blind crossover phase. (ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IV; CI = confidence interval; LDX = lisdexamfetamine dimesylate; LS = least squares). * P < .0001 LDX vs placebo.
Figure 4 ADHD-RS-IV total scores at baseline and visit 5/6 and difference in LS mean (95% CI) between LDX and placebo during the double-blind crossover phase. (ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IV; CI = confidence interval; LDX = lisdexamfetamine dimesylate; LS = least squares). * P < .0001 LDX vs placebo.CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 15 Not checked · 79 Own results and interpretations

48 more claims

Create a free account to see all 95 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 29
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 34 references

Cited by

See all 138

Metadata

Authors
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group
Affiliations
University of California, Irvine (US)
Corresponding author
Wigal, Timothy
Venue
Behavioral and Brain Functions
Published
2010
Volume
6
Issue
1
Pages
34
ISSN
1744-9081 (ISSN-L)
OpenAlex
W2127512142
Cited by
136
References
34
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 13 · 2014: 19 · 2013: 14 · 2012: 18
FWCI
10.90
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Behavioral and Brain Functions (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
Keywords
lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, adult ADHD, sustained attention, ADHD-RS-IV, treatment-emergent adverse events, stimulant efficacy
MeSH terms
Lisdexamfetamine Dimesylate, Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotropic Drugs, Time Factors, Work, Treatment Outcome, Cross-Over Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. https://app.cochat.ai/papers/10.1186/1744-9081-6-34
The paper
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group. (2010). Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral and Brain Functions. https://doi.org/10.1186/1744-9081-6-34

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.